1.Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Byung Sup KIM ; Ho Jun SEOL ; Do Hyun NAM ; Chul Kee PARK ; Il Han KIM ; Tae Min KIM ; Jeong Hoon KIM ; Young Hyun CHO ; Sang Min YOON ; Jong Hee CHANG ; Seok Gu KANG ; Eui Hyun KIM ; Chang Ok SUH ; Tae Young JUNG ; Kyung Hwa LEE ; Chae Yong KIM ; In Ah KIM ; Chang Ki HONG ; Heon YOO ; Jin Hee KIM ; Shin Hyuk KANG ; Min Kyu KANG ; Eun Young KIM ; Sun Hwan KIM ; Dong Sup CHUNG ; Sun Chul HWANG ; Joon Ho SONG ; Sung Jin CHO ; Sun Il LEE ; Youn Soo LEE ; Kook Jin AHN ; Se Hoon KIM ; Do Hun LIM ; Ho Shin GWAK ; Se Hoon LEE ; Yong Kil HONG
Cancer Research and Treatment 2017;49(1):193-203
PURPOSE: The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample. MATERIALS AND METHODS: A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively. RESULTS: After the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients, respectively. The methylation status of O6-methylguanine-DNA methyltransferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up period was 16.3 months and the median overall survival (OS) was 17.5 months. The actuarial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively. The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-, 3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy alone, regardless of the methylation status of the MGMT promoter. Patients with a methylated MGMT promoter also showed a significantly longer OS and PFS than those with an unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period. CONCLUSION: Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment.
Biopsy
;
Chemoradiotherapy*
;
Disease-Free Survival
;
Follow-Up Studies
;
Glioblastoma*
;
Humans
;
Korea*
;
Methylation
;
Radiotherapy
;
Retrospective Studies*
;
Survival Rate
2.Development of Monoclonal Antibodies for Diagnosis of Plasmodium vivax.
Nguyen Thi Phuong LINH ; Hyun PARK ; Jinyoung LEE ; Dong Xu LIU ; Ga Eun SEO ; Hae Jin SOHN ; Jin Hee HAN ; Eun Taek HAN ; Ho Joon SHIN ; Seon Ju YEO
The Korean Journal of Parasitology 2017;55(6):623-630
Plasmodium lactate dehydrogenase (pLDH) is a strong target antigen for the determination of infection with Plasmodium species specifically. However, a more effective antibody is needed because of the low sensitivity of the current antibody in many immunological diagnostic assays. In this study, recombinant Plasmodium vivax LDH (PvLDH) was experimentally constructed and expressed as a native antigen to develop an effective P. vivax-specific monoclonal antibody (mAb). Two mAbs (2CF5 and 1G10) were tested using ELISA and immunofluorescence assays (IFA), as both demonstrated reactivity against pLDH antigen. Of the 2 antibodies, 2CF5 was not able to detect P. falciparum, suggesting that it might possess P. vivax-specificity. The detection limit for a pair of 2 mAbs-linked sandwich ELISA was 31.3 ng/ml of the recombinant antigen. The P. vivax-specific performance of mAbs-linked ELISA was confirmed by in vitro-cultured P. falciparum and P. vivax-infected patient blood samples. In conclusion, the 2 new antibodies possessed the potential to detect P. vivax and will be useful in immunoassay.
Antibodies
;
Antibodies, Monoclonal*
;
Diagnosis*
;
Enzyme-Linked Immunosorbent Assay
;
Fluorescent Antibody Technique
;
Humans
;
Immunoassay
;
L-Lactate Dehydrogenase
;
Limit of Detection
;
Plasmodium vivax*
;
Plasmodium*
3.Differential and correlated expressions of p16/p21/p27/p38 in mammary gland tumors of aged dogs.
Hyun Woo KIM ; Jung Hyung JU ; Jong Il SHIN ; Byung Joon SEUNG ; Jung Hyang SUR
Journal of Veterinary Science 2017;18(4):479-485
The inhibitory effect of neutering on mammary gland tumor development in dogs has been well described. However, we observed that the effect of neutering on tumor malignancy may be altered by aging. Therefore, we characterized mammary tumors in aged dogs by analyzing the expression of cellular senescence markers. Expressions of p16, p38, p21, and p27 antibodies, which are senescence-associated markers, were assessed in canine mammary tumors of aged dogs via immunohistochemical analysis. In addition, correlations between those expressions were analyzed. Expression of p16 was negatively associated with strong nuclear p27 expression. Expression of p38 was observed in most of the mammary tumors examined, and negative p38 expression was related to positive p21 expression. Moreover, p21 expression was associated with p27 expression; negative p21 expression was associated with negative p27 expression, while positive p21 expression was associated with positive p27 expression. The results confirm that the p21- and p27-encoding genes have similar expression patterns in the mammary tumors of aged dogs. In the present study, we characterized the expression of cellular senescence markers in these tumors and elucidated the relationships among their expression patterns.
Aging
;
Animals
;
Antibodies
;
Cell Aging
;
Dogs*
;
Mammary Glands, Human*
;
Mammary Neoplasms, Animal
4.STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma.
Sung Hoon JUNG ; Seo Yeon AHN ; Hyun Woo CHOI ; Myung Geun SHIN ; Seung Shin LEE ; Deok Hwan YANG ; Jae Sook AHN ; Yeo Kyeoung KIM ; Hyeoung Joon KIM ; Je Jung LEE
Blood Research 2017;52(4):293-299
BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) is not only a key signaling molecule in the regulation of growth but is also involved in malignant transformation. We investigated the prognostic significance of STAT3 expression in 94 non-elderly adult patients (aged 38 to 65 yr) with newly diagnosed multiple myeloma (MM). METHODS: Tumor cell-specific phosphotyrosine-STAT3 (PY-STAT3) expression at the time of diagnosis was evaluated with dual immunohistochemical (IHC) staining for PY-STAT3 and CD138. RESULTS: PY-STAT3 positivity was detected in 10 patients (10.6%), including three who showed strong expression. PY-STAT3-positive patients had higher serum C-reactive protein and calcium levels at diagnosis than did PY-STAT3-negative patients. PY-STAT3 positivity had predictive value for poor progression-free survival (PFS; P=0.001) and overall survival (OS; P=0.003). Among the 60 patients who received frontline autologous stem cell transplantation, PY-STAT3-positive patients had poorer PFS than did PY-STAT3-negative patients (4.2 vs. 19.2 mo, respectively; P=0.013). Multivariate analysis identified PY-STAT3 expression as an independent prognostic factor for PFS (relative risk [RR]=2.706, P=0.014) and OS (RR=3.091, P=0.044). CONCLUSION: These data show that PY-STAT3 positivity, as determined using dual IHC, is a marker of poor prognosis in non-elderly adult patients with MM.
Adult*
;
C-Reactive Protein
;
Calcium
;
Diagnosis
;
Disease-Free Survival
;
Humans
;
Multiple Myeloma*
;
Multivariate Analysis
;
Prognosis
;
STAT3 Transcription Factor
;
Stem Cell Transplantation
5.The association between skeletal maturation and adrenal androgen levels in obese children and adolescents.
Sung Eun KIM ; Joon Weon JANG ; Moon Bae AHN ; Shin Hee KIM ; Won Kyoung CHO ; Kyoung Soon CHO ; So Hyun PARK ; Min Ho JUNG ; Byoung Kyu SUH
Annals of Pediatric Endocrinology & Metabolism 2017;22(2):108-114
PURPOSE: This study aimed to investigate the association between skeletal maturation and adrenal androgen levels in obese children and adolescents. METHODS: Fifty-three children and adolescents (aged 7–15 years) diagnosed as obese or overweight were investigated. Anthropometric measurements, bone age (BA) determination, serum biochemical analyses, and hormonal measurements were performed. The difference between BA and chronological age (BA–CA, dBACA) was calculated and used to represent the degree of advanced skeletal maturation. RESULTS: Thirty-one subjects were classified into the obese group and 22 subjects into the overweight group. Insulin resistance as calculated by the homeostasis model assessment of insulin resistance (HOMA-IR) was significantly higher in the obese group than in the overweight group (4.03±2.20 vs. 2.86±1.11, P=0.026). The skeletal maturation of the obese group was advanced, but the dBACA did not differ between the obese and overweight groups statistically (1.43±1.35 vs. 0.91±1.15, P=0.141). Serum dehydroepiandrosterone sulfate (DHEA-S) levels were significantly higher in subjects with dBACA>1 compared to those with dBACA≤1 (104.3±62.2 vs. 59.6±61.0, P=0.014). Correlation analyses demonstrated that dBACA was positively correlated with body mass index standard deviation scores (r=0.35, P=0.010), fasting insulin (r=0.36, P=0.009), HOMA-IR (r=0.30, P=0.031), and insulin-like growth factor-binding protein-3 (r=0.331, P=0.028). In multivariate linear regression analysis, HOMA-IR (P=0.026) and serum DHEA-S (P=0.032) were positively correlated with the degree of advanced skeletal maturation. CONCLUSION: Advanced skeletal maturation is associated with increased insulin resistance and elevated DHEA-S levels in obese children and adolescents.
Adolescent*
;
Age Determination by Skeleton
;
Androgens
;
Body Mass Index
;
Child*
;
Dehydroepiandrosterone Sulfate
;
Fasting
;
Homeostasis
;
Humans
;
Insulin
;
Insulin Resistance
;
Linear Models
;
Obesity
;
Overweight
6.Effect of Rifaximin on Hepatic Fibrosis in Bile Duct-ligated Rat Model.
Seung Kak SHIN ; Oh Sang KWON ; Jong Joon LEE ; Yeon Ho PARK ; Cheol Soo CHOI ; Sung Hwan JEONG ; Duck Joo CHOI ; Yun Soo KIM ; Ju Hyun KIM
The Korean Journal of Gastroenterology 2017;70(5):239-246
BACKGROUND/AIMS: The translocation of bacteria and their lipopolysaccharides from the gut can promote fibrosis in cirrhotic patients. The aim of this study was to investigate the effects of rifaximin on hepatic fibrosis in a bile duct-ligated rat model. METHODS: The bile duct ligation (BDL) was carried out for eight days (acute injury model: sham-operated rats [G1], BDL rats [G2], and BDL rats treated with rifaximin [G3]) or 22 days (chronic injury model: sham-operated rats [G4], BDL rats [G5], and BDL rats treated with rifaximin [G6]). Rifaximin (50 mg/kg/day) was administered daily via gavage after BDL. Liver function, serum tumor necrosis factor-alpha (TNF-α), and hepatic hydroxyproline levels were measured. Moreover, a histological analysis of fibrosis contents was performed using sirius red stain. RESULTS: In the acute injury model, the liver function and TNF-α level were not improved after the rifaximin treatment. The hydroxyproline levels (µg/g liver tissue) in G1, G2, and G3 were 236.4±103.1, 444.8±114.4, and 312.5±131.6, respectively; and fibrosis contents (%) were 0.22±0.04, 1.64±0.53, and 1.66±0.44, respectively. The rifaximin treatment did not ameliorate acute BDL-induced fibrosis. In the chronic injury model, the hydroxyproline levels in G4, G5, and G6 were 311.5±72.9, 1,110.3±357.9, and 944.3±209.3, respectively; and fibrosis contents (%) were 0.19±0.03, 5.04±0.18, and 4.42±0.68, respectively (G5 vs. G6, p=0.059). The rifaximin treatment marginally ameliorated chronic BDL-induced fibrosis. CONCLUSIONS: Rifaximin did not reduce inflammation and fibrosis in bile duct-ligated rat model.
Animals
;
Bacteria
;
Bile Ducts
;
Bile*
;
Fibrosis*
;
Humans
;
Hydroxyproline
;
Inflammation
;
Ligation
;
Lipopolysaccharides
;
Liver
;
Liver Cirrhosis
;
Models, Animal*
;
Rats*
;
Tumor Necrosis Factor-alpha
7.Prestroke Antiplatelet Effect on Symptomatic Intracranial Hemorrhage and Functional Outcome in Intravenous Thrombolysis.
Jay Chol CHOI ; Ji Sung LEE ; Tai Hwan PARK ; Yong Jin CHO ; Jong Moo PARK ; Kyusik KANG ; Kyung Bok LEE ; Soo Joo LEE ; Jae Guk KIM ; Jun LEE ; Man Seok PARK ; Kang Ho CHOI ; Joon Tae KIM ; Kyung Ho YU ; Byung Chul LEE ; Mi Sun OH ; Jae Kwan CHA ; Dae Hyun KIM ; Hyun Wook NAH ; Dong Eog KIM ; Wi Sun RYU ; Beom Joon KIM ; Hee Joon BAE ; Wook Joo KIM ; Dong Ick SHIN ; Min Ju YEO ; Sung Il SOHN ; Jeong Ho HONG ; Juneyoung LEE ; Keun Sik HONG
Journal of Stroke 2016;18(3):344-351
BACKGROUND AND PURPOSE: About 30%-40% of stroke patients are taking antiplatelet at the time of their strokes, which might increase the risk of symptomatic intracranial hemorrhage (SICH) with intravenous tissue plasminogen activator (IV-TPA) therapy. We aimed to assess the effect of prestroke antiplatelet on the SICH risk and functional outcome in Koreans treated with IV-TPA. METHODS: From a prospective stroke registry, we identified patients treated with IV-TPA between October 2009 and November 2014. Prestroke antiplatelet use was defined as taking antiplatelet within 7 days before the stroke onset. The primary outcome was SICH. Secondary outcomes were discharge modified Rankin Scale (mRS) score and in-hospital mortality. RESULTS: Of 1,715 patients treated with IV-TPA, 441 (25.7%) were on prestroke antiplatelet. Prestroke antiplatelet users versus non-users were more likely to be older, to have multiple vascular risk factors. Prestroke antiplatelet use was associated with an increased risk of SICH (5.9% vs. 3.0%; adjusted odds ratio [OR] 1.79 [1.05-3.04]). However, at discharge, the two groups did not differ in mRS distribution (adjusted OR 0.90 [0.72-1.14]), mRS 0-1 outcome (34.2% vs. 33.7%; adjusted OR 1.27 [0.94-1.72), mRS 0-2 outcome (52.4% vs. 52.9%; adjusted OR 1.21 [0.90-1.63]), and in-hospital mortality (6.1% vs. 4.2%; adjusted OR 1.19 [0.71-2.01]). CONCLUSIONS: Despite an increased risk of SICH, prestroke antiplatelet users compared to non-users had comparable functional outcomes and in-hospital mortality with IV-TPA therapy. Our results support the use of IV-TPA in eligible patients taking antiplatelet therapy before their stroke onset.
Hospital Mortality
;
Humans
;
Intracranial Hemorrhages*
;
Odds Ratio
;
Platelet Aggregation Inhibitors
;
Prospective Studies
;
Risk Factors
;
Stroke
;
Thrombolytic Therapy
;
Tissue Plasminogen Activator
8.Association between Depression and Sociodemographic Factors of Elderly Welfare Facility Users in a City.
Ae Rin SHIN ; Kang Joon LEE ; Hyun KIM
Korean Journal of Psychosomatic Medicine 2016;24(2):133-139
OBJECTIVES: As the prevalence of elderly depression increases, it becomes urgent problem to provide preventive and management measures. But in practice, it is difficult to detect depression in early stage. The purpose of this study is to evaluate the association between sociodemographic factors and depression in elderly welfare facility users in a city. METHODS: In this research, the severity of depression and sociodemographic factors(gender, age, education, comorbid disease, housing type, number of children, number of family members living with the subjects) was evaluated through PHQ-9 and interview. Using the data, the associations of depression and sociodemographic factors were analyzed. Based on PHQ-9 depression cut-off value(10 points), the subjects were divided into two groups, and the difference of the variables between groups were analyzed statistically. RESULTS: ‘Own house’(YES/NO), education(less than elementary school graduation/more than elementary school graduation) were sociodemographic factors which showed significance difference in mean PHQ-9 scores. Group with Over PHQ-9 10 points showed less ‘having their own house’ and less education level than group with less PHQ-9 10 points. CONCLUSIONS: With this research, it is expected that the risk factors for the elderly depression can be understood and the measures for early detection and invention of elderly depression would be provided.
Aged*
;
Child
;
Depression*
;
Education
;
Housing
;
Humans
;
Inventions
;
Prevalence
;
Risk Factors
9.Validation of the Korean Version of the DN4 Diagnostic Questionnaire for Neuropathic Pain in Patients with Lumbar or Lumbar-Radicular Pain.
Ho Joong KIM ; Joon Hee PARK ; Didier BOUHASSIRA ; Jae Hoon SHIN ; Bong Soon CHANG ; Choon Ki LEE ; Chang Hyun BAEK ; Jin S YEOM
Yonsei Medical Journal 2016;57(2):449-454
PURPOSE: To evaluate the diagnostic value of the Korean version of the Douleur Neuropathique 4 (DN4) questionnaire and to validate this questionnaire in terms of psychometric properties in patients with chronic pain due to degenerative spinal disease. MATERIALS AND METHODS: The Korean version of the DN4 questionnaire, which was translated and linguistically validated by the MAPI Research Group, was tested on 83 patients with lumbar or lumbar-radicular pain. Test-retest reliability was evaluated in a subsample of 40 patients who completed two assessments with an interval of 2 weeks. Nociceptive pain and neuropathic component pain were diagnosed in 40 and 43 patients, respectively. RESULTS: The Cronbach's alpha coefficient of internal consistency was 0.819, and the test-retest intraclass correlation coefficient (3, 1) (95% confidence interval) was 0.813 (0.776-0.847) (n=40). The area under the receiver-operator characteristics curve was 0.953 (p<0.001), with 95% confidence interval between 0.869 and 0.990. The Korean version of the DN4 questionnaire showed a sensitivity of 100% and 87.1%, and a specificity of 88.2% and 94.1% at the cutoff value of 3/10 and 4/10, respectively, for discriminating neuropathic component pain. CONCLUSION: The present study demonstrated the good discriminatory power of DN4 between nociceptive pain and neuropathic component pain in patients with lumbar or lumbar-radicular pain.
Adult
;
Aged
;
Aged, 80 and over
;
Chronic Pain/*diagnosis
;
Female
;
Humans
;
Male
;
Middle Aged
;
Neuralgia/*diagnosis
;
Pain Measurement/*methods
;
Psychometrics
;
Reproducibility of Results
;
Sensitivity and Specificity
;
Surveys and Questionnaires/*standards
;
Translating
10.Comparative Analysis of Liver Injury-Associated Cytokines in Acute Hepatitis A and B.
So Youn SHIN ; Sook Hyang JEONG ; Pil Soo SUNG ; Jino LEE ; Hyung Joon KIM ; Hyun Woong LEE ; Eui Cheol SHIN
Yonsei Medical Journal 2016;57(3):652-657
PURPOSE: Acute hepatitis A (AHA) and acute hepatitis B (AHB) are caused by an acute infection of the hepatitis A virus and the hepatitis B virus, respectively. In both AHA and AHB, liver injury is known to be mediated by immune cells and cytokines. In this study, we measured serum levels of various cytokines and T-cell cytotoxic proteins in patients with AHA or AHB to identify liver injury-associated cytokines. MATERIALS AND METHODS: Forty-six patients with AHA, 16 patients with AHB, and 14 healthy adults were enrolled in the study. Serum levels of 17 cytokines and T-cell cytotoxic proteins were measured by enzyme-linked immunosorbent assays or cytometric bead arrays and analyzed for correlation with serum alanine aminotransferase (ALT) levels. RESULTS: Interleukin (IL)-18, IL-8, CXCL9, and CXCL10 were significantly elevated in both AHA and AHB. IL-6, IL-22, granzyme B, and soluble Fas ligand (sFasL) were elevated in AHA but not in AHB. In both AHA and AHB, the serum level of CXCL10 significantly correlated with the peak ALT level. Additionally, the serum level of granzyme B in AHA and the serum level of sFasL in AHB correlated with the peak ALT level. CONCLUSION: We identified cytokines and T-cell cytotoxic proteins associated with liver injury in AHA and AHB. These findings deepen the existing understanding of immunological mechanisms responsible for liver injury in acute viral hepatitis.
Acute Disease
;
Adult
;
Alanine Transaminase/blood
;
Biomarkers/blood
;
Cytokines/*blood
;
Enzyme-Linked Immunosorbent Assay
;
Fas Ligand Protein/blood
;
Female
;
Hepatitis A/blood/virology
;
Hepatitis A virus/*genetics/immunology
;
Hepatitis B/blood/virology
;
Hepatitis B virus/*genetics/immunology
;
Humans
;
Interleukin-6/blood
;
Interleukin-8/blood
;
Interleukins/blood
;
Liver Failure/immunology/metabolism/*pathology
;
Male
;
Middle Aged
;
T-Lymphocytes, Cytotoxic/immunology/*metabolism

Result Analysis
Print
Save
E-mail